A Phase II Trial of TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Apr 2018
At a glance
- Drugs Durvalumab (Primary) ; TPIV 200 (Primary)
- Indications Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 04 Apr 2018 According to a TapImmune media release, interim results from this study are expected in 2H 2018.
- 28 Feb 2018 Planned End Date changed from 1 May 2018 to 1 May 2019.
- 28 Feb 2018 Planned primary completion date changed from 1 May 2018 to 1 May 2019.